期刊
SCIENCE ADVANCES
卷 8, 期 28, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abn0050
关键词
-
资金
- NIH [T32GM007055, F30HL154554, T32GM007267, T32HL007284, R01DK121055, R01MH116694, R01NS097726, P01HL120840]
- Deutsche Forschungsgemeinschaft [IRTG 1902-2, IRTG 1902-1]
This study demonstrates the protective and preventive effects of an antibody against oxidized phosphatidylcholines (OxPCs) at different stages of nonalcoholic fatty liver disease (NAFLD). It provides evidence that individual OxPC species independently affect disease initiation and progression, and that adeno-associated virus (AAV)-mediated expression of the antibody is an effective therapeutic intervention.
Oxidized phosphatidylcholines (OxPCs) are implicated in chronic tissue damage. Hyperlipidemic LDL-R--deficient mice transgenic for an OxPC-recognizing IgM fragment (scFv-E06) are protected against nonalcoholic fatty liver disease (NAFLD). To examine the effect of OxPC elimination at different stages of NAFLD progression, we used cre-dependent, adeno-associated virus serotype 8-mediated expression of the single-chain variable fragment of E06 (AAV8-scFv-E06) in hepatocytes of albumin-cre mice. AAV8-induced expression of scFv-E06 at the start of FPC diet protected mice from developing hepatic steatosis. Independently, expression of scFv-E06 in mice with established steatosis prevented the progression to hepatic fibrosis. Mass spectrometry-based oxophospho-lipidomics identified individual OxPC species that were reduced by scFv-E06 expression. In vitro, identified OxPC species dysregulated mitochondrial metabolism and gene expression in hepatocytes and hepatic stellate cells. We demonstrate that individual OxPC species independently affect disease initiation and progression from hepatic steatosis to steatohepatitis, and that AAV-mediated expression of scFv-E06 is an effective therapeutic intervention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据